European Cystic Fibrosis Conference 2017 (June 07-10, 2017, Seville, Spain)
|Publication Type||Conference paper|
S.aureus is one of the most abundant pathogens causing life-threatening infections in cystic fibrosis (CF) patients. The most worldwide spread antibiotic resistant type of S.aureus is MRSA . Except resistance to β-lactam antibiotics there are increased reports of vancomycin resistant VRSA phenotype. Today, there were no patients with VRSA detected in CF, however, it is possible to assume that it may become a challenge in the nearest future. The aim of the present study was to evaluate clinical efficacy of nebulized solution of novel antimicrobial drug candidate Mul-1867 (poly-N1-hydrazino(imino)methyl-1,6-hexanediamine) in murine models caused by MRSA/VRSA infection.
The MICs were determined in accordance with the CLSI guidelines. The antibiofilm effect was studied against 12, 24, 48 or 72h MRSA/VRSA biofilms. 8-weeks old C57BL/6 mice were intranasally infected with MRSA or VRSA (each 5×104 cfu/mouse) strain. Treatment was started 12, 24, 48 or 72h after infection with Mul-1867 or Vancomycin, both administered by inhalation at 8x MIC.
Mul-1867 exhibited a high level of antimicrobial activity with the MICs from 0.06 to 0.5 mg/L against both MRSA and VRSA. Vancomycin was less active: the MICs 0.5 mg/L for MRSA and more than 64 mg/L against VRSA. The minimal biofilm eradication concentration for Mul-1867 varied from 1 to 8 times the MIC, and from 4 to 128 times the MIC for Vancomycin against 12-72-h-old MRSA or VRSA biofilms.
Based on the analysis of the spread of antibiotic resistance, most likely VRSA will be come an issue for CF within the next decade.
Existing medicines cannot address the future need against VRSA infections
Mul-1867 is highly effective against preformed MRSA/VRSA biofilms. And its activity is not significantly decreased as biofilm matures
MRSA/VRSA lung infections are characterized with the linear increase of mortality due to the delay in antibiotic therapy
The effect of Mul 1867 is less sensitive to the time of treatment initiation than VAN
|Year of Publication||2017|
|Journal||Journal of Cystic Fibrosis Vol. 16, Suppl 1, June 2017. Abstracts of the 40th ECFC (June 07–10, 2017, Seville, Spain)|
© Copyright TGV-inhalonix 2016. All rights reserved.